Aminosuberoyl hydroxamic acids (ASHAs): a potent new class of HDAC inhibitors.
Bioorg Med Chem Lett
; 17(14): 3969-71, 2007 Jul 15.
Article
em En
| MEDLINE
| ID: mdl-17507219
ABSTRACT
Histone deacetylase (HDAC) inhibitors that target Class I and Class II HDACs are currently in advanced clinical trials for the treatment of cancer. Vorinostat (Zolinza, SAHA) is a hydroxamic acid approved for the treatment of patients with cutaneous T-cell lymphoma who have progressive, persistent or recurrent disease on or following two systemic therapies. As part of an on-going effort to better understand the nature of the HDAC enzyme/inhibitor interaction and design highly effective HDAC inhibitors, we herein report the design, synthesis and HDAC inhibitory activity of a vorinostat-derived series of substrate-based HDAC inhibitors.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Inibidores Enzimáticos
/
Inibidores de Histona Desacetilases
/
Ácidos Hidroxâmicos
Limite:
Animals
Idioma:
En
Ano de publicação:
2007
Tipo de documento:
Article